Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

New strategies in the management of Guillain-Barré syndrome.

Xiao J, Simard AR, Shi FD, Hao J.

Clin Rev Allergy Immunol. 2014 Dec;47(3):274-88. doi: 10.1007/s12016-013-8388-5. Review.

PMID:
24057598
2.

[Cellular aspect of neuroinflammation in Guillain-Barré syndrome: a key to a new therapeutic option?].

Créange A, Sharshar T, Raphaël JC, Gherardi R.

Rev Neurol (Paris). 2002 Jan;158(1):15-27. Review. French.

PMID:
11938319
3.

Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.

Zhang HL, Zheng XY, Zhu J.

Cytokine Growth Factor Rev. 2013 Oct;24(5):443-53. doi: 10.1016/j.cytogfr.2013.05.005. Epub 2013 Jun 21. Review.

PMID:
23791985
4.

Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?

Wu X, Wang J, Liu K, Zhu J, Zhang HL.

Expert Opin Ther Targets. 2016;20(2):209-22. doi: 10.1517/14728222.2016.1086751. Epub 2015 Sep 10. Review.

PMID:
26357850
5.

CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome.

Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Tithi HR, Ubogu EE.

PLoS One. 2014 Mar 14;9(3):e90463. doi: 10.1371/journal.pone.0090463. eCollection 2014.

6.

Therapeutic strategies in the Guillain-Barré syndrome.

Kieseier BC, Hartung HP.

Semin Neurol. 2003 Jun;23(2):159-68. Review.

PMID:
12894381
7.

The role of chemokines in Guillain-Barré syndrome.

Chiang S, Ubogu EE.

Muscle Nerve. 2013 Sep;48(3):320-30. doi: 10.1002/mus.23829. Epub 2013 Jul 27. Review.

8.

Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?

Zhang HL, Wu L, Wu X, Zhu J.

Expert Opin Ther Targets. 2014 Apr;18(4):355-63. doi: 10.1517/14728222.2014.882899. Epub 2014 Jan 30. Review.

PMID:
24479493
9.

The role of cytokines in Guillain-Barré syndrome.

Lu MO, Zhu J.

J Neurol. 2011 Apr;258(4):533-48. doi: 10.1007/s00415-010-5836-5. Epub 2010 Nov 23. Review.

PMID:
21104265
10.

Guillain-Barré syndrome.

Newswanger DL, Warren CR.

Am Fam Physician. 2004 May 15;69(10):2405-10. Review.

11.

Tumor necrosis factor-α in Guillain-Barré syndrome, friend or foe?

Wang Y, Zhang J, Luo P, Zhu J, Feng J, Zhang HL.

Expert Opin Ther Targets. 2017 Jan;21(1):103-112. Epub 2016 Nov 18. Review.

PMID:
27817222
12.

Novel therapeutic approaches to Guillain-Barré syndrome.

Pritchard J.

Expert Opin Investig Drugs. 2000 Oct;9(10):2307-18. Review.

PMID:
11060808
13.

The Guillain-Barré syndrome.

Fujimura H.

Handb Clin Neurol. 2013;115:383-402. doi: 10.1016/B978-0-444-52902-2.00021-7. Review.

PMID:
23931791
14.

Plasma exchange for Guillain-Barré syndrome.

Raphaël JC, Chevret S, Hughes RA, Annane D.

Cochrane Database Syst Rev. 2002;(2):CD001798. Review. Update in: Cochrane Database Syst Rev. 2012;7:CD001798.

PMID:
12076424
15.

Guillain-Barré syndrome.

Esposito S, Longo MR.

Autoimmun Rev. 2017 Jan;16(1):96-101. doi: 10.1016/j.autrev.2016.09.022. Epub 2016 Sep 23. Review.

PMID:
27666816
16.

[Guillain-Barre syndrome: etiology and pathogenesis].

Avila-Funes JA, Mariona-Montero VA, Melano-Carranza E.

Rev Invest Clin. 2002 Jul-Aug;54(4):357-63. Review. Spanish.

PMID:
12415961
17.

Advances in the management of Guillain-Barré syndrome.

Green DM.

Curr Neurol Neurosci Rep. 2002 Nov;2(6):541-8. Review.

PMID:
12359110
18.

Antiganglioside antibodies in Guillain-Barré syndrome and its related conditions.

Shahrizaila N, Yuki N.

Expert Rev Neurother. 2011 Sep;11(9):1305-13. doi: 10.1586/ern.11.114. Review.

PMID:
21864076
19.

Plasma exchange for Guillain-Barré syndrome.

Raphaël JC, Chevret S, Hughes RA, Annane D.

Cochrane Database Syst Rev. 2001;(2):CD001798. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD001798.

PMID:
11406009
20.

Guillain-Barré syndrome (GBS).

Pithadia AB, Kakadia N.

Pharmacol Rep. 2010 Mar-Apr;62(2):220-32. Review.

Supplemental Content

Support Center